The Allergic Rhinitis Market Was Worth About $10 Billion in 2006 and Has Been Decreasing In Value Over the Last Few Years

Research and Markets (http://www.researchandmarkets.com/reports/c74575) has announced the addition of Commercial and Pipeline Insight: Allergic Rhinitis to their offering.

Introduction

The allergic rhinitis market will continue to decline over the next few years, after which it will resume limited growth due to the introduction of new compounds and combination products. These will drive the expansion of sales in existing classes as they exhibit safety and convenience advantages. Meanwhile, immunotherapy is expected to move from its niche position into mainstream therapy.

Scope

Indication-based forecasts for allergic rhinitis products and significant pipeline drugs

Assessment of country-specific drivers and resistors likely to impact the market

Future market outlook for individual products taking into account key market events, in particular patent expiry and competitor launch dates

Assessment of the remaining unmet clinical needs in allergic rhinitis, analyzing the potential of new targeted therapies

Highlights

The allergic rhinitis market was worth about $10 billion in 2006 and has been decreasing in value over the last few years due to patent expiries and limited levels of innovation. The top 2 drug classes prescribed for the treatment of allergic rhinitisoral antihistamines and nasal corticosteroids accounted for 77% of the total sales in this market.

At least 3 major allergic rhinitis players have developed and launched an oral antihistamine/decongestant fixed dose combination. However, several practical concerns have limited the use of these treatments and none of the products have reached sales as high as their single antihistamine component.

The immunotherapy market is moving from a niche position towards baseline therapy. We expect a sublingual tablet for the treatment of grass allergy (such as Grazax) to be able to reach annual sales of $780m to $1.3 billion, depending on the patient population targeted, the length of administration and price of the product.

Reasons to Purchase

Identify key opportunities and threats that will impact the use and uptake of new and existing products

Quantify the future size and scope of the allergic rhinitis market and predict the future performance of key compounds

Understand and capitalize on clinical unmet needs in the market, either through lifecycle management of marketed drugs or new product development

ABOUT OUR HEALTHCARE

About the Respiratory and Infectious Disease pharmaceutical analysis team

CHAPTER 1 EXECUTIVE SUMMARY

CHAPTER 2 MARKET DEFINITION AND OVERVIEW

CHAPTER 3 COUNTRY MARKET ASSESSMENTS

CHAPTER 4 DRUG ANALYSIS & FORECASTS

BIBLIOGRAPHY

APPENDIX A – MARKET DATA AND MAJOR BRAND KEY FACTS

APPENDIX B – MARKET FORECAST DATA

APPENDIX C

List of Tables

List of Figures

Companies Mentioned:

ALK-Abelló

Allergopharma

Allergy Therapeutics

CMP Therapeutics

Cobalis

Curalogic

Cytos Biotechnology

Dynavax

Fornix Biosciences

GlaxoSmithKline

Greer Laboratories

HAL Allergy

Merck & Co

Pfizer

Sanofi-Aventis

Schering-Plough

Sepracor

Stallergènes

UCB

For more information visit http://www.researchandmarkets.com/reports/c74575

Source: Datamonitor